heckel medizintechnik GmbH   Report issue

For profit Phase 2
Founded: Esslingen Germany (1994)
Status: No NME R&D (1994)

Organization Overview

First Clinical Trial
2019
NCT03787290
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

heckel medizintechnik GmbH

Active Ingredients

Drugs in Phase 2 Trials (1)

tocilizumab (actemra) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Depression (Phase 2)

Depressive Disorder (Phase 2)

Depressive Disorder, Major (Phase 2)

Fever (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1